Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCOAT trial: Prophylactic endoscopic variceal ligation in high-risk esophageal varices receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
KCT0010242Phase 2Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Asan Medical Center. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0010242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010242.